MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board
Members
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the
Company will nominate Ms. Karin Eastham and Dr. Marc Cluzel as new members of
the Supervisory Board at the Company's Annual Shareholder Meeting on Thursday,
May 31, 2012. Ms. Eastham and Dr. Cluzel will replace Prof. Dr. Jürgen Drews and
Dr. Metin Colpan. Prof. Drews has been a member of MorphoSys AG's Supervisory
Board since 1998, while Dr. Colpan joined in 2004.
"We are delighted to be able to present two highly qualified candidates for
MorphoSys's Supervisory Board," commented Dr. Gerald Möller, Chairman of the
Supervisory Board of MorphoSys AG. "Karin Eastham and Marc Cluzel both have
outstanding track records in our industry and have contributed to the successful
performance of several companies over the course of their careers."
Karin Eastham is an experienced financial executive who currently serves as
director on the Corporate Boards of Illumina, Inc., Amylin, Inc., Trius
Therapeutics, Inc. and Geron Corporation. From May 2004 to September 2008, she
served as Executive Vice President and Chief Operating Officer and as a member
of the Board of Trustees of the Burnham Institute for Medical Research, a non-
profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms.
Eastham served as Senior Vice President, Finance, Chief Financial Officer and
Secretary of Diversa Corporation. She previously held similar positions with
CombiChem, Inc. and Cytel Corporation. She also held several positions,
including Vice President, Finance, at Boehringer Mannheim Diagnostics, from
1976 to 1988. Ms. Eastham received a B.S. and a M.B.A. from Indiana University
and is a Certified Public Accountant.
Dr. Marc Cluzel, an established innovator and leader in the pharmaceutical
industry, has more than 20 years of extensive knowledge and experience in
Research & Development and product registration in the USA, Europe and Japan.
Dr. Cluzel founded C&F consulting in 2011 and serves also as Executive Vice
President of Product Development at HÙYÀ Bioscience International, LLC. Dr.
Cluzel served as global head of R&D for Sanofi from 2007 to 2011, as Executive
Vice President of Research & Development for Sanofi (Formerly Sanofi-Aventis SA)
and before 2009 as its Senior Vice President of Science and Medical Affairs. He
was also since 2002 chairman and CEO of Sanofi-Synthelabo R&D France then
Sanofi-Aventis R&D France. His career began in hospital medical care and
gradually transitioned to research at Johns Hopkins University, Baltimore and
Guy's Hospital, London. Dr. Cluzel holds both an MD and a PhD from the
University of Montpellier, France.
The full agenda for the Annual General Meeting is available on the Company's
website under www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
generate superior monoclonal antibodies for research and diagnostic
applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®) and
arYla(®) are registered trademarks of MorphoSys. Ylanthia(®) and 100 billion
high potentials(TM) are trademarks of MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release:
http://hugin.info/130295/R/1603237/506731.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1603237]
Unternehmensinformation / Kurzprofil:
Datum: 18.04.2012 - 07:31 Uhr
Sprache: Deutsch
News-ID 136204
Anzahl Zeichen: 6601
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 294 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Nominates Karin Eastham and Marc Cluzel as New Supervisory Board Members"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
